FFO
FATE icon

Fortitude Family Office’s Fate Therapeutics FATE Stock Holding History

Fortitude Family Office’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.22K Buy
822
+395
+93% +$731 ﹤0.01% 1448
2026
Q1 		$512 Sell
427
-93
-18% -$113 ﹤0.01% 1720
2025
Q4 		$511 Buy
+520
New +$624 ﹤0.01% 1703
2025
Q3 		– Sell
-391
Closed -$438 – 2034
2025
Q2 		$438 Buy
+391
New +$454 ﹤0.01% 1868

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fortitude Family Office's FATE Position: Q2 2026 in Review

Fortitude Family Office increased its Fate Therapeutics (FATE) stake by 93% in Q2 2026, buying an estimated $731 and bringing the position to 822 shares worth $2.22K. The position accounts for ﹤0.01% of the portfolio, ranked #1448.

Fortitude Family Office first reported a position in FATE in Q2 2025 and has held it in 4 quarters since. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Fortitude Family Office held 822 shares of Fate Therapeutics worth $2.22K as of Q2 2026.
  • Fortitude Family Office bought 395 Fate Therapeutics shares in Q2 2026, an estimated $731.
  • Fate Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1448 holding.
  • Fortitude Family Office first reported a position in Fate Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.